Bristol-Myers Squibb Lung Cancer Drug Looks Promising in Clinical TrialResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Hall, M. (2020, October 16). Bristol-Myers Squibb Lung Cancer Drug Looks Promising in Clinical Trial. Asbestos.com. Retrieved February 1, 2023, from https://www.asbestos.com/news/2012/05/30/bristol-lung-cancer-drug-promising/
Hall, Mark. "Bristol-Myers Squibb Lung Cancer Drug Looks Promising in Clinical Trial." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2012/05/30/bristol-lung-cancer-drug-promising/.
Hall, Mark. "Bristol-Myers Squibb Lung Cancer Drug Looks Promising in Clinical Trial." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2012/05/30/bristol-lung-cancer-drug-promising/.
Pharmaceutical giant Bristol-Myers Squibb is developing a new drug that may be uniquely effective against lung cancer, among other diseases.
The drug’s progress through clinical trials is noted for its ability to “unleash the body’s T-cells” to fight against cancer cells, Bloomberg reported.
Lung cancer is diagnosed in nearly 200,000 Americans each year, making it the most common cause of cancer-related deaths in the country.
Early results of the drug’s effect shows real hope for patients battling this all-too prevalent disease.
“This could be a breakthrough for lung cancer,” said Julie Brahmer, an oncologist from the Johns Hopkins Kimmel Cancer Center.
The disease is caused primarily by smoking and secondhand smoke, but also can be caused by asbestos exposure and exposure to radon.
Bristol’s drug, currently known as BMS-936558, utilizes a defense against particular immune system functions. Within the trial, the drug is attacking melanoma and is encouraging these T-cells to battle off the cancer.
Encouraging Trial Results
The first phase of the clinical trial, which is executed for the purpose of gaining regulatory approval, hinted at signs of success.
In a group of 240 patients, BMS-936558 shrunk the tumors of 13 out of 75 lung cancer patients. For melanoma patients, 24 of 95 patients noticed shrunken tumors, while 10 of 33 kidney cancer patients saw their tumors shrink as well.
While some perceive these limited results as relatively inconsequential, researchers remain hopeful because they strive to use this treatment as a “backbone” for combined treatment options that may arise in the future.
In addition to Bristol’s drug, chemotherapy could be applied to fend off the immune system from cancer cells, says Seamus Fernandez, an a analyst at equity research company Leerink Swann & Co.
“It is the early stage of a whole new field of cancer therapy.”
Fernandez further predicts that the company may earn over $4 billion a year through sales of the drug, if it progresses through all clinical stages and enters the market.
Reports show that based on the drug’s positive results, the company plans to skip the second phase and move forward into the last stages of the human trials where testing on lung cancer, melanoma and kidney cancer continues.
These last trials would begin later this year for lung and kidney cancer, while the testing on melanoma wouldn’t begin until 2013.
Competition Could Benefit Cancer Patients
According to Bloomberg, Bristol is competing against at least five other companies that are developing similar drugs aimed at the same cancer-targeting approach.
These other drug makers include Merck & Co., Whitehouse Station, GlaxoSmithKline, Roche Holding AG and Teva Pharmaceutical Industries Ltd.
For the hundreds of thousands of lung cancer patients who may have not-so bright prognoses, a fast race to the finish line among drug manufacturers could be a great thing.
Bristol appears to be in the lead.
Lung cancer is the second-second most common cancer in the United States and treatment options normally consist of surgery, chemotherapy and radiation therapy, or a combination of the three.
David Gobin is one patient who participated in the clinical trial for Bristol’s experimental drug and has stated positive results after the treatment.
“This is a miracle drug for me,” said Gobin.
He says that he is breathing more easily and gained nearly 20 pounds after losing it. Furthermore, he plans to play golf for the first time in years.